Skip to content
OpenCapital
Get started

Ocular Therapeutix OCUL Accrued Progress Collections and Price Adjustments

Accrued Progress Collections and Price Adjustments at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
——
Envista Holdings Corporation logo
Envista Holdings CorporationNVST
——
Henry Schein logo
Henry ScheinHSIC
——

Other financials

Income statement

See full
Revenue$10.8M+0.8%
Gross profit$9.5M+0.2%
Operating income-$93.3M-46.0%
Net income-$88.6M-38.3%
EPS (diluted)-$0.40-5.3%

Balance sheet

See full
Cash & equivalents$666.7M+90.7%
Total debt$79.5M+4.2%
Total equity$581.6M+119%
Total assets$732.5M+80.5%

Cash flow

See full
Operating cash flow-$66.0M-47.7%
CapEx$4.7M+141%
Free cash flow-$70.7M-51.6%

Valuation

See full
Market cap$2.21B+58.2%
Enterprise value$1.63B+40.8%
P/S42.6×+19.1×

Profitability

See full
Gross margin87.2%-3.4pp
Operating margin-575.4%+1,233pp
Net margin-558.2%+1,493pp
FCF margin-463%+2,860pp

Returns & leverage

See full
Return on equity-68.6%+17.0pp
Debt / equity0.1×-0.2×
Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ocular Therapeutix's accrued progress collections and price adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ocular Therapeutix's accrued progress collections and price adjustments?
Ocular Therapeutix (OCUL) reported accrued progress collections and price adjustments of $14M in Q1 2026.
How has Ocular Therapeutix's accrued progress collections and price adjustments changed year-over-year?
Ocular Therapeutix's accrued progress collections and price adjustments decreased by 0.0% year-over-year, from $14M to $14M.
What is the long-term trend for Ocular Therapeutix's accrued progress collections and price adjustments?
Over 5 years (2020 to 2025), Ocular Therapeutix's accrued progress collections and price adjustments has grown at a 3.1% compound annual growth rate (CAGR), from $12M to $14M.